Splicing analysis of the engineered SRSF2 mutated (Mut) lines replicated the aberrant splicing phenotype observed in primary AML samples, which is dominated by abnormal exon usage (Figure 1A, Data S2). This evidence concerns the gene SRSF2 and acute myeloid leukemia.